Multiples Myelom (Plasmozytom)

Sie befinden sich hier:

  • DSMMXIV (Multiples Myelom, Primär)
    Lenalidomide, Adriamycin, Dexamethasone (RAD) versus Lenalidomide, Bortezomib, Dexamethasone (VRD) For Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Transplantation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)
    Status: offen.
    Synopse